ALBT vs. FNCH, ELOX, KRBP, GMDAQ, TCBP, WINT, TCON, SCNI, FRTX, and NSTGQ
Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Finch Therapeutics Group (FNCH), Eloxx Pharmaceuticals (ELOX), Kiromic BioPharma (KRBP), Gamida Cell (GMDAQ), TC Biopharm (TCBP), Windtree Therapeutics (WINT), TRACON Pharmaceuticals (TCON), Scinai Immunotherapeutics (SCNI), Fresh Tracks Therapeutics (FRTX), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.
Avalon GloboCare (NASDAQ:ALBT) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Finch Therapeutics Group has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,304.14%. Avalon GloboCare's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.
Finch Therapeutics Group received 10 more outperform votes than Avalon GloboCare when rated by MarketBeat users.
1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 64.0% of Avalon GloboCare shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Avalon GloboCare has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
Avalon GloboCare has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avalon GloboCare and Avalon GloboCare both had 2 articles in the media. Avalon GloboCare's average media sentiment score of 1.44 beat Finch Therapeutics Group's score of 0.75 indicating that Avalon GloboCare is being referred to more favorably in the media.
Summary
Avalon GloboCare beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.
Get Avalon GloboCare News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalon GloboCare Competitors List
Related Companies and Tools
